Author:
Wang Kunpeng,Wang Cong,Jiang Hao,Zhang Yaqiong,Lin Weidong,Mo Jinggang,Jin Chong
Abstract
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide and is increasing in incidence. Local ablative therapy plays a leading role in HCC treatment. Radiofrequency (RFA) is one of the first-line therapies for early local ablation. Other local ablation techniques (e.g., microwave ablation, cryoablation, irreversible electroporation, phototherapy.) have been extensively explored in clinical trials or cell/animal studies but have not yet been established as a standard treatment or applied clinically. On the one hand, single treatment may not meet the needs. On the other hand, ablative therapy can stimulate local and systemic immune effects. The combination strategy of immunotherapy and ablation is reasonable. In this review, we briefly summarized the current status and progress of ablation and immunotherapy for HCC. The immune effects of local ablation and the strategies of combination therapy, especially synergistic strategies based on biomedical materials, were discussed. This review is hoped to provide references for future researches on ablative immunotherapy to arrive to a promising new era of HCC treatment.
Funder
Zhejiang Province Public Welfare Technology Application Research Project
Natural Science Foundation of Zhejiang Province
Science and Technology Plan Project of Taizhou
Medical Science and Technology Project of Zhejiang Province
Taizhou University
Subject
Immunology,Immunology and Allergy
Reference154 articles.
1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA: Cancer J Clin,2021
2. Hepatocellular Carcinoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up;Vogel;Ann Oncol,2018
3. Pan-Asian Adapted ESMO Clinical Practice Guidelines for the Management of Patients With Intermediate and Advanced/Relapsed Hepatocellular Carcinoma: A TOS-ESMO Initiative Endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO;Chen;Ann Oncol,2020
4. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline;Gordan;J Clin Oncol,2020
5. Guidelines Insights: Hepatobiliary Cancers, Version 2.2019;Benson;J Natl Compr Cancer Netw: JNCCN,2019
Cited by
50 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献